Vivera Pharmaceuticals, a US-based pharmaceutical company, announced on Thursday that it has added Guido Jouret, PhD to the company's board of advisors as senior technology advisor and interim chief technology officer.
Dr Jouret has over 25 years of leadership experience across various technology sectors, such as software, services, networking, cloud platforms, and hardware. He has served as chief digital officer of ABB. Prior to ABB, Dr Jouret was with Cisco Systems, Inc., where he spent seven years in its Emerging Technologies Group. He has served as general manager of Cisco, president of Digital Platforms for Envision Energy, chief technology officer at Nokia Technologies, several executive-level roles for notable companies, including chief development officer for Plume.
Paul Edalat, Vivera chairman and CEO, said, 'Dr Jouret has an impressive track record for leading and developing technology-centric businesses. Vivera is looking forward to utilising Dr Jouret's expertise as the company moves past the engineering stage of ZICOH (Vivera's patented, high-tech, dose-controlled, electronic prescription delivery device) and begins to develop the hardware and software for the device and begins to lay the framework for the overall commercialisation strategy.'
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval